On Feb. 24, 2020, Moderna announced it had released the first batch of mRNA-1273, the Company’s vaccine against the novel coronavirus, for human use. Vials of mRNA-1273 had been shipped to the NIH to be used in the planned Phase 1 study in the U.S.